Review of patients who had nail reconstruction after melanoma surgery
Official title: Review of the Literature and Retrospective, Single-centre Study of a Series of Patients Who Underwent Reconstruction After Complete Nail Resection.
Run by Centre Hospitalier Universitaire de Nice · NCT06861023 · Data updated 2026-11-12
This study looks at how well different nail reconstruction methods work for patients who had melanoma surgery instead of having their nails amputated.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 1 site (Nice, Alpes Maritimes) |
| Status | Recruiting |
| Started | January 15, 2025 |
| Main results expected | February 28, 2025 |
| Study ends | March 25, 2025 |
| Registry record updated | March 6, 2025 |
| Trial ID | NCT06861023 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients who have undergone enlarged resection of the nail apparatus due to acral melanoma of the fingers or toes.
✕Probably not a fit
Patients who have undergone amputation or those who oppose participation in the study will not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study reviews patients who underwent reconstruction of the nail apparatus following wide local excision due to melanoma. It focuses on cases where the standard treatment of amputation was replaced with enlarged excision of the nail plate, allowing for various reconstruction techniques. The investigators present a series of patients treated with INTEGRA (dermal matrix) and skin grafts to assess outcomes and effectiveness. The observational nature of the study allows for a comprehensive analysis of patient experiences and results.
Why it matters
Potential benefit: If successful, this study could provide insights into effective reconstruction techniques that preserve finger or toe function and appearance after melanoma treatment.
How similar studies have gone: While this approach is less common, similar studies have shown promising outcomes in reconstructive techniques for melanoma, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who have undergone enlarged resection of the nail apparatus with immediate or delayed reconstruction in the setting of acral melanoma of the fingers or toes. Exclusion Criteria: * Patients who have amputation, opposition of the pateint to the study.
Where it's running
-
Chu Nice
Nice, Alpes Maritimes, France Recruiting
Study contacts
- Study coordinator: Elise Lupon
- Email: lupon.e@chu-nice.fr
- Phone: 06 26 30 63 23
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Melanoma treatment with immunotherapy guided by serial ctDNA testing
This trial tests whether regular ctDNA blood tests during treatment can help tailor the plan for patients with advanced melanoma receiving nivolumab and ipilimumab.
-
Non-invasive skin-tape test to detect melanoma using methylation biomarkers
A non-invasive skin-tape test is being tried to see if it can detect melanoma in people who are about to have a biopsy for a suspicious pigmented lesion.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
BL-M08D treatment in melanoma and other solid tumors
A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.
-
Aggressive lipid lowering in melanoma patients starting immune checkpoint therapy
This trial tests whether lowering cholesterol aggressively can reduce heart artery disease risk in melanoma patients who are just beginning immune checkpoint therapy.
-
Timing of Immunotherapy in Melanoma
This trial tests whether starting standard melanoma immunotherapy earlier in the day (before 10 am) versus later in the day (after 1 pm) makes a difference for patients with unresectable or metastatic melanoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.